German Accelerator Life Sciences (GALS) Partner Ada Health Expands to the US Upon Closing $47M Funding Round

German Accelerator Life SciencesAI health companion, Ada Health intensifies collaboration with German Accelerator Life Sciences (GALS) as it expands to the US. Following the successful closing of a $47M funding round, Ada will accelerate operational and partnership developments in a rapidly growing US market. The London and Berlin-based health technology company has developed a health companion and telemedicine app as well as a decision support tool for medical professionals, which launched in late 2016. With its sophisticated AI engine paired to a vast medical knowledge base, Ada has become one of the fastest growing medical apps in 2017, with over 1.5M people using Ada to assess their health. This rapid growth is reflected by the substantial $47M financial backing they secured from lead investor Access Industries, and including the AI entrepreneur behind Amazon Alexa, William Tunstall-Pedoe and Google's Chief Business Officer Philipp Schindler.

The German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry of Economic Affairs (BMWi), will advise on the development and implementation of Ada’s US market strategy with its experienced mentor team and extensive network of partners and industry experts.

"The US has become one of our fastest growing markets," said Daniel Nathrath, CEO and Founder of Ada. "Our operational expansion, along with our new team of medical advisors and collaboration with GALS, will help us identify the most effective ways to integrate our solution into the US healthcare ecosystem and maximise the impact we deliver to patients."

"Healthcare systems are under extreme pressure," added Dr. Claire Novorol, Founder and Chief Medical Officer of Ada. "There's a tremendous potential for Ada’s assessment technology to improve personalized health support and positively transform the way in which patients and doctors interact, in the US and globally."

"We believe Ada is positioned to become a leading global health management player," commented Christoph Lengauer, CEO of the German Accelerator. "GALS is excited to be collaborating with Ada on this expansion into the US. We will leverage our deep industry network and expertise to support their continued success."

"Ada has developed one of the most highly innovative and sophisticated health assessment tools on the market," commented Thomas Kiessling, GALS mentor and former Chief Product and Innovation Officer at Deutsche Telekom. "We see many potential opportunities where Ada can add value to the US life sciences industry."

Ada's personal health companion interacts with patients via a conversational interface to identify their symptoms and suggest possible causes. As a follow up, patients in the UK have the option to remotely consult with a general practitioner through Ada's Doctor Chat. The German version of the App was launched early this month and aims to follow the extended UK model in the near future.

As part of the European Union's Horizon 2020 Research and Innovation Programme (Ada2020), Ada has also developed a decision support tool for general practitioners and specialists. After years of years refining our medical content and reasoning capabilities, along with continuous learning from medical experts, Ada provides an advanced decision support system and is now able to support doctors with their diagnosis for even the most complex and rare cases.

About Ada

Ada Health is an innovative health technology company that believes everyone in the world should have access to quality, personalized health information and care. Developed by a team of doctors, scientists and engineers, Ada Health launched its conversational health companion app to empower people with personalized medical insights and identify appropriate next steps. Supported by a sophisticated AI engine and curated medical knowledge base, Ada also augments doctors by providing earlier health information and decision support. Ada's personal health companion app is available on iOS and Android and has been one of the fastest growing medical apps in 2017, ranked #1 in over 130 countries. You can find more information about Ada at www.ada.com.

About the German Accelerator Life Sciences

The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi) with the goal of helping German startups and young companies succeed in the global marketplace. GALS, centrally located and highly connected in the world’s leading life sciences innovation hub in Cambridge, Massachusetts, offers support in multiple areas: from operational assistance to high end mentoring and strategic guidance by experienced industry experts and key opinion leaders.

Most Popular Now

Open Call SC1-DTH-01-2019: Big Data and …

Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of...

Cerner Selected for NHS Framework to Sup…

Integrated Care Systems (ICS) and Sustainability and Transformation Partnerships (STPs) aim to deliver the best possible quality of health and care, shift to value-based care and proactively improve outcomes for...

Brainlab and Magic Leap Partner in Digit…

Brainlab has announced a strategic development partnership with Florida-based Magic Leap, a developer of proprietary spatial computing solutions that help users enrich their real world experience by integrating digital content...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites...

Whole-Brain Connectome Maps Teach Artifi…

Medical University of South Carolina (MUSC) neurologists have developed a new method based on artificial intelligence that may eventually help both patients and doctors weigh the pros and cons of...

Oxehealth Secures World-First Accreditat…

The British Standards Institute (BSI) has accredited Oxehealth's vital signs measurement software as a Class IIa medical device in Europe. This is the first time that software enabling a digital...

MEDICA 2018: The Starting Block for Many…

12 - 15 November 2018, Düsseldorf, Germany. MEDICA, the world’s leading medical trade fair in Düsseldorf which attracts over 5,000 exhibitors from around 70 countries, is becoming an even bigger hotspot...

MEDICA 2018 Presents the Future of Medic…

12 - 15 November 2018, Düsseldorf, Germany. Artificial intelligence, Big Data or IoT (Internet of Things) - we would be hard pressed to find a sector that doesn’t have these terms...

Artificial Intelligence for Health: ITU …

The ITU Focus Group on 'AI for Health' (FG-AI4H), created in collaboration with the World Health Organization (WHO), has issued a Call for Proposals to identify compelling use cases of...

Siemens Healthineers and STORZ MEDICAL P…

On the occasion of the 70th annual congress of the German Society for Urology, DGU, Siemens Healthineers and STORZ MEDICAL have announced plans to enter into a sales partnership agreement...

Spinal Cord Stimulation, Physical Therap…

Spinal cord stimulation and physical therapy have helped a man paralyzed since 2013 regain his ability to stand and walk with assistance. The results, achieved in a research collaboration between...

Sandoz Healthcare Access Challenge #Sand…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators...